Harvard Bioscience (HBIO) Asset Writedowns and Impairment (2010 - 2020)
Harvard Bioscience (HBIO) posted quarterly Asset Writedowns and Impairment of $763000.0 for Q4 2020, up 819.81% year-over-year from $82951.8 in Q1 2020, and up 18975.0% quarter-over-quarter from $4000.0 in Q1 2020.
Harvard Bioscience (HBIO) Asset Writedowns and Impairment (2010 - 2020) Analysis & Trends
Harvard Bioscience (HBIO) has reported Asset Writedowns and Impairment for 11 consecutive years, with $763000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Asset Writedowns and Impairment rose 819.81% year-over-year to $763000.0; the TTM figure through Dec 2020 stood at $767000.0 (down 53.32% YoY), while the FY2020 annual figure was $787000.0, up 173.26% from the prior year.
- Asset Writedowns and Impairment grew to $763000.0 in Q4 2020 per HBIO's latest filing, from $4000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $941000.0 in Q2 2019 and bottomed at -$411000.0 in Q4 2016.
- Historically, Asset Writedowns and Impairment has averaged $176800.0 across 5 years, with a median of $22000.0 in 2018.
- Annual changes were most pronounced in 2016 — Asset Writedowns and Impairment tumbled 13600.0% — and 2019, when it jumped 6860.0%.
- Harvard Bioscience's Asset Writedowns and Impairment stood at -$411000.0 in 2016, then soared by 73.24% to -$110000.0 in 2017, then jumped by 120.0% to $22000.0 in 2018, then plunged by 581.82% to -$106000.0 in 2019, then jumped by 819.81% to $763000.0 in 2020.
- Business Quant data shows HBIO's Asset Writedowns and Impairment at $763000.0 in Q4 2020, $4000.0 in Q1 2020, and -$106000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 763,000.00 |
| Dec 31, 2020 | 763,000.00 |
| Mar 31, 2020 | 4,000.00 |
| Mar 31, 2020 | 4,000.00 |
| Dec 31, 2019 | -106,000.00 |
| Dec 31, 2019 | -106,000.00 |
| Sep 30, 2019 | 460,000.00 |
| Sep 30, 2019 | 460,000.00 |
| Jun 30, 2019 | 941,000.00 |
| Jun 30, 2019 | 941,000.00 |
| Mar 31, 2019 | 348,000.00 |
| Mar 31, 2019 | 348,000.00 |
| Dec 31, 2018 | 22,000.00 |
| Dec 31, 2018 | 22,000.00 |
| Mar 31, 2018 | 5,000.00 |
| Mar 31, 2018 | 5,000.00 |
| Dec 31, 2017 | -110,000.00 |
| Dec 31, 2017 | -110,000.00 |
| Jun 30, 2017 | 31,000.00 |
| Jun 30, 2017 | 31,000.00 |